

Drug Class Review Monograph – GPI Class 07 – Aminoglycosides

Review Time Frame: 02/2016 – 04/2017

Previous Class Review: 05/2016

Background:

Aminoglycosides bind to the aminoacyl site of 16S ribosomal RNA within the 30S ribosomal subunit of susceptible bacteria. Abnormal, nonfunctional proteins are formed due to misreading of the bacterial DNA. Susceptible bacteria eventually die because of the lack of functional proteins.

New treatment guideline recommendations:

- None identified

Newly approved drugs:

- None identified

Newly approved formulations:

- None identified

Newly approved generics:

- None identified

Discontinued drugs:

- None identified

FDA Safety Alerts/black box warnings:

- None identified

Pipeline alerts:

Agents pending FDA approval include:

- None identified

References:

1. Drew RH. Aminoglycosides. Hooper DC, Bloom A. (Ed), UpToDate. Waltham MA. Accessed May 2017.
2. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.; 2016. URL: <http://www.clinicalpharmacology-ip.com/>. Updated April 2016.
3. Food and Drug Administration. [WWW.FDA.GOV](http://www.fda.gov). Accessed May 2017.
4. Envolve Pharmacy Solutions internal pipeline database. Accessed May 2017.